The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index; 124 of the 302 sources its claims cite were checked for support.
Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits
Open accessAbstract
Description: The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings. Methods: The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review. Recommendations: Key takeaways included the following: Clinicians should engage in ongoing risk–benefit assessment of BZD use/tapering, clinicians should utilize shared decision-making strategies in collaboration with patients, clinicians should not discontinue BZDs abruptly in patients who are likely to be physically dependent and at risk of withdrawal, clinicians should tailor tapering strategies to each patient and adjust tapering based on patient response, and clinicians should offer patients adjunctive psychosocial interventions to support successful tapering.
Overview
CoChat Summary
## TL;DR
This 2025 ASAM-led joint clinical practice guideline gives evidence-informed and consensus-based recommendations for tapering benzodiazepines when risks outweigh benefits. It emphasizes patient-centered, shared decision-making; gradual, individualized dose reductions; and special considerations for opioids, substance use disorders, psychiatric disorders, pregnancy, and older adults.
## Key findings
- The guideline’s systematic literature review identified 57 relevant articles, but few directly addressed the core questions; therefore, most recommendations are based on clinical consensus, and 3 recommendation statements are based on low-quality evidence from 10 studies.
- For tapering, clinicians should generally start with 5% to 10% dose reductions, and the taper should typically not exceed 25% every 2 weeks; the guideline also notes that tapering may take a year or more for long-term users.
- In a retrospective cohort of 353,576 US commercial claims patients, discontinuing benzodiazepines over 6 months was associated with 1.6 times higher mortality risk than continued use, but the guideline cautions that the reason for discontinuation and taper speed were not measured.
- For adjunctive support, a Cochrane review found moderate-quality evidence that CBT during tapering improved discontinuation at 1 month and 3 months; a meta-analysis of brief primary-care interventions found higher discontinuation at 6 months (RR 2.73) and 12 months (RR 3.41).
- In inpatient phenobarbital protocols, one case series of 310 patients reported 27% sedation, 17% self-discharge, 1% delirium, and no falls or seizures; another chart review of 355 patients reported no seizures, falls, or sedation and 5% self-discharge.
## Methods
- Design: Joint clinical practice guideline developed by ASAM and partner societies using modified GRADE methodology, a clinical consensus process, a systematic literature review, targeted supplemental searches, and external stakeholder review.
- Sample/data: The review considered adults using one or more benzodiazepines for at least 2–4 weeks, including those with benzodiazepine use disorder; the systematic review identified 57 relevant articles.
- Analysis: The guideline used PICO-formulated clinical questions, GRADE for evidence-based recommendations, and a modified Delphi process for consensus statements when evidence was lacking.
## Limitations
- Stated in the paper: The paper repeatedly notes a paucity of evidence on benzodiazepine tapering; few studies directly answered the core questions, and many recommendations are consensus-based rather than evidence-based.
- Stated in the paper: There were no direct trials comparing tapering strategies for many key questions, and several recommendations rely on limited or low-quality evidence.
- Evident from the text: Much of the evidence comes from outpatient settings, retrospective studies, or heterogeneous interventions, so generalizability to all settings and patient groups appears limited (as indicated by the guideline’s emphasis on individualized care and uncertain evidence).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
96 Valid · 7 Not valid · 82 Not checked · 113 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“with data from 2014 to 2016 indicating over one-third of BZD prescriptions were co-prescribed with opioids.14,19”
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > INTRODUCTION > Background
What the sources say
- Not checked — no full text of the sourcecites [14] Santo L, Rui P, Ashman JJ. Physician office visits at which benzodiazepines were prescribed: findings from 2014-2016 National Ambulatory Medical Care Survey. Natl Health Stat Report. 2020;(137):1-16.
- Disputedcites [19] Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399-e187399. https://doi.org/10.1001/jamanetworkopen.2018.7399 sourceExperimental — accuracy not yet measured
The Results (Coprescribing and Predictors Associated With Use) report that opioids were coprescribed in 26.4% of 2015 visits involving a benzodiazepine, not over one-third. The Discussion says the study's data extend through 2015, not 2016. The paper measures visits rather than the share of benzodiazepine prescriptions. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Some older adults have taken BZDs continuously for decades.9,14,15”
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > INTRODUCTION > Background
What the sources say
- Not checked — no full text of the sourcecites [9] Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-142. https://doi.org/10.1001/jamapsychiatry.2014.1763 source
- Not checked — no full text of the sourcecites [14] Santo L, Rui P, Ashman JJ. Physician office visits at which benzodiazepines were prescribed: findings from 2014-2016 National Ambulatory Medical Care Survey. Natl Health Stat Report. 2020;(137):1-16.
- Supportedcites [15] Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33(7):1223-1237. https://doi.org/10.1017/s0033291703008213 source
The Abstract reports that 27% of the study’s older patients had taken BZDs continuously for more than 20 years. The Discussion likewise says 27% had taken them every night for more than 20 years, directly supporting “some older adults” and “for decades.” (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite potential harms, long-term use of BZDs (i.e., ≥ 120 days) is common.9,10”
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > INTRODUCTION > Background
What the sources say
- Not checked — no full text of the sourcecites [9] Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-142. https://doi.org/10.1001/jamapsychiatry.2014.1763 source
- Partly supportedcites [10] Gerlach LB, Maust DT, Leong SH, Mavandadi S, Oslin DW. Factors associated with long-term benzodiazepine use among older adults. JAMA Intern Med. 2018;178(11):1560-1562. https://doi.org/10.1001/jamainternmed.2018.2413 sourceExperimental — accuracy not yet measured
The Results report that 26.4% of newly prescribed older adults met the paper’s definition of long-term benzodiazepine use. But the Methods define long-term use as a medication possession ratio greater than 30% over one year, not ≥120 days; the paper therefore does not establish how common use meeting the cited threshold is. The study is also limited to low-income older adults in Pennsylvania (Discussion). (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given that both BZDs and opioids cause CNS depression, concomitant use increases the risk of adverse events, including fatal and nonfatal overdose.21–23”
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > INTRODUCTION > Background
What the sources say
- Partly supportedcites [21] Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. https://doi.org/10.1136/bmj.j760 sourceExperimental — accuracy not yet measured
The Results report an association between concurrent use and emergency visits or hospital admissions for opioid overdose; the Discussion also reports earlier studies linking concurrent use to fatal overdose. But this retrospective study does not establish that concurrent use causes the increased risk: its Abstract explicitly qualifies the proposed effect of eliminating concurrent use with “If this association is causal.” (LLM, conf=0.86)
- Partly supportedcites [22] Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. https://doi.org/10.1136/bmj.h2698 sourceExperimental — accuracy not yet measured
The Discussion reports an association between concurrent benzodiazepine and opioid receipt and fatal overdose among veterans receiving opioid analgesics. Its Findings in context section also reports another study's association with combined fatal and nonfatal overdoses. But the paper explicitly says its observational design cannot establish that concomitant use causes overdose deaths, so the claim's causal wording overstates the evidence. (LLM, conf=0.86)
- Not matchedcites [23] US Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Co-prescribing of BZDs and opioids quadrupled between 2003 and 2015 in ambulatory care settings”
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > INTRODUCTION > Background
What the sources say
- Not checked — no full text of the sourcecites [14] Santo L, Rui P, Ashman JJ. Physician office visits at which benzodiazepines were prescribed: findings from 2014-2016 National Ambulatory Medical Care Survey. Natl Health Stat Report. 2020;(137):1-16.
- Supportedcites [19] Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399-e187399. https://doi.org/10.1001/jamanetworkopen.2018.7399 source
The Results section (“Coprescribing and Predictors Associated With Use”) reports that benzodiazepine and opioid prescriptions noted in a single ambulatory-care visit quadrupled, from 0.5% to 2.0%. The study covers 2003 through 2015. The measure is same-visit coprescribing, rather than all overlapping prescriptions. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
165 more claims · 59 with their cited sources checked
Create a free account to see all 298 claims and to verify the 2 references still open.
- It may state two separate claims as one. 62
- Probably not a substantial claim. 78
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“No medications are approved for benzodiazepine withdrawal, and the ASAM panel concluded ‘After carefully considering existing evidence on various pharmacological interventions…no single medication had enough data to support recommending it’ (p. 61) (Brunner et al., 2025), consistent with other analyses (Baandrup et al., 2018; Welsh et al., 2018).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brunner et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Guidelines universally recommend tapering benzodiazepines, yet there is no definitive method, and most advice is based on expert consensus rather than empirical evidence or pharmacological principles, resulting in conflicting advice (Brunner et al., 2025; Pollmann, Murphy, Bergman, & Gardner, 2015).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brunner et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Guidelines universally recommend tapering benzodiazepines, yet there is no definitive method, and most advice is based on expert consensus rather than empirical evidence or pharmacological principles, resulting in conflicting advice (Brunner et al., 2025; Pollmann, Murphy, Bergman, & Gardner, 2015).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brunner et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2025, a joint clinical practice guideline on benzodiazepine tapering developed by the American Society of Addiction Medicine (ASAM), funded by the FDA, partnered with nine other medical societies including the American Psychiatric Association, recommended linear dose reductions as the preferred strategy (5%–10% of the daily dose every 2–4 weeks) (Brunner et al., 2025).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brunner et al., 2025
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Even short-term use of benzodiazepines may be problematic, because physiologic dependence on benzodiazepines can occur after two to four weeks of use [84–89].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [89]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > SUMMARY OF RECOMMENDATIONS
“Recommendation for Older Adults 27.Clinicians should generally taper BZD medication in older adults unless there are compelling reasons for continuation (Clinical Consensus, Strong Recommendation).”
§ Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits > POPULATION-SPECIFIC CONSIDERATIONS > Older Adults
“Recommendation for Older Adults 29. Clinicians should generally taper BZD medication in older adults unless there are compelling reasons for continuation (Clinical Consensus, Strong Recommendation).”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“158,159 Clinicians should educate patients regarding potential rebound psychiatric symptoms and how they will be managed and offer or refer for appropriate mental health services.”
Shared decision making: A model for clinical practice
Elwyn, G., Frosch, D., Thomson, R., Joseph-Williams, N., Lloyd, A., Kinnersley, P., Cording, E., Tomson, D., Dodd, C., Rollnick, S., et al. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2077-6 · Cited by 4,405
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886 · cited 6×
“139 This includes minimizing opioid doses where possible and optimizing non-opioid interventions for managing pain, such as nonpharmacological treatments for pain management, including exercise, mindfulness-based interventions, and CBT. 139 The CDC guideline, and the joint US Department of Veterans…”
InfluentialYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 1×
“39–41 Long-term BZD use may also be appropriate for medical conditions such as complex seizure disorders, 42 spasticity, 43,44 sleep disorders involving abnormal movements (e.g., rapid eye movement (REM) sleep behavior disorder, restless leg syndrome), 45 and catatonia.”
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18372 · Cited by 1,597
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Where Is the Evidence? A Systematic Review of Shared Decision Making and Patient Outcomes
Shay, L. A., & Lafata, J. E. (2015) · Medical Decision Making · doi:10.1177/0272989x14551638 · Cited by 1,214 · cited 2×
“64 When BZD tapering is indicated, clinicians should initiate a conversation with patients with a goal of shared decision-making.”
Research works printed but not linked: 12
- Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002.
- Horowitz M, Taylor DM. Chapter 3: Safe Deprescribing of Benzodiazepines and Z-drugs. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. WILEY Blackwell; 2024.
- European Monitoring Centre for Drugs and Drug Addiction. New benzodiazepines in Europe - a review. Luxembourg: Publications Office of the European Union; 2021.
- Dikeos DG, Soldatos CR. The pharmacotherapy of insomnia: efficacy and rebound with hypnotic drugs. Prim Care Companion J Clin Psychiatry. 2002;4(Suppl 1):27-32.
- Aronson JK ed. Meyler’s Side Effects of Drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th ed. Elsevier; 2016.
- Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002.
- Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182:498-504. https://doi.org/10.1192/bjp.182.6.498 · DOI · Paper page
- Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.
- Lähteenmäki R, Puustinen J, Vahlberg T, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77(6):975-985. https://doi.org/10.1111/bcp.12294 · DOI · Paper page
- Ashton CH. Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual). Institute of Neuroscience, Newcastle University; 2002.
- Barros VV, Opaleye ES, Demarzo M, et al. Effects of mindfulness-based relapse prevention on the chronic use of hypnotics in treatment-seeking women with insomnia: a randomized controlled trial. Int J Behav Med. 2022;29(3):266-277. https://doi.org/10.1007/s12529-021-10002-4 · DOI
- Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16(5):424-431. https://doi.org/10.1089/bfm.2020.0259 · DOI · Paper page
Cited by
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7
New Benzodiazepine Tapering Guide—Slow and Patient Centered
Brunner, E., Boyle, M. P., & Maust, D. T. (2025) · JAMA · doi:10.1001/jama.2025.6047 · Cited by 5
Self-citationOpioid use disorder and concurrent benzodiazepine use: clinical risks and management strategies
Fakhri, A., Ritvo, A. D., Casarella, J., & Tang, Y. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2593244 · Cited by 4
“30,38,39”
Gireesh, H., Shukla, L., Shivaprakash, P., Mukherjee, A., Chand, P., & Murthy, P. (2025) · Drug and Alcohol Review · doi:10.1111/dar.70059 · Cited by 5
Lenze, E. J., Karp, J. F., Gebara, M. A., Nicol, G. E., & Mulsant, B. H. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02338-w · Cited by 7
Metadata
- Authors
- Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., Sanders, A. E., Snodgrass, B., VandenBerg, A., Wright, T., Boyle, M., Devoto, A., Framnes-DeBoer, S., Kleykamp, B., Norrington, J., Lindsay, D., Clinical Guideline Committee (CGC) Members, Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., Sanders, A. E., Snodgrass, B., VandenBerg, A., Wright, T., Contractors, A. S. A., Boyle, M., Devoto, A., Framnes-DeBoer, S., Kleykamp, B., Norrington, J., & Lindsay, D.
- Venue
- Journal of General Internal Medicine
- Published
- 2025-06-17
- Volume
- 40
- Issue
- 12
- Pages
- 2814-2859
- ISSN
- 0884-8734 (ISSN-L)
- 1525-1497
- PMC
- PMC12463801
- OpenAlex
- W4411388475
- Cited by
- 51
- References
- 206
- Citations by year
- 2026: 41 · 2025: 10
- FWCI
- 30.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of General Internal Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Food and Drug Administration (U01FD007804)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- benzodiazepine tapering, benzodiazepine withdrawal, benzodiazepine dependence, risk-benefit assessment, shared decision-making, physical dependence, psychosocial interventions, drug discontinuation
- MeSH terms
- Drug Tapering, Benzodiazepines, Humans, Substance Withdrawal Syndrome, Risk Assessment, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. https://app.cochat.ai/papers/10.1007/s11606-025-09499-2
- The paper
- Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., Sanders, A. E., Snodgrass, B., VandenBerg, A., Wright, T., Boyle, M., Devoto, A., Framnes-DeBoer, S., Kleykamp, B., Norrington, J., . . . Lindsay, D. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-025-09499-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

